Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195389 | 0.85 | HBB (0.76) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3177866 | 0.85 | TP53 (0.71) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL13417536 | 0.82 | NPSR1 (0.76) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3186505 | 0.81 | NPSR1 (0.70) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3186151 | 0.80 | HTT (0.69) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3196915 | 0.79 | NPSR1 (0.70) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3203581 | 0.78 | NPSR1 (0.63) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3188569 | 0.77 | HTT (0.67) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3191651 | 0.76 | HTT (0.66) | NPSR1GAATP53MAPTKDM4E | |
| SCHEMBL3190854 | 0.76 | NPSR1 (0.68) | NPSR1GAATP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007115232-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | NPSR1 2297/4885GAA 1982/4885TP53 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.